blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4032544

EP4032544 - NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  16.06.2023
Database last updated on 25.09.2024
FormerThe application has been published
Status updated on  24.06.2022
Most recent event   Tooltip11.12.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
Immatics Biotechnologies GmbH
Paul-Ehrlich-Strasse 15
72076 Tübingen / DE
[2022/30]
Inventor(s)01 / ALTEN, Leonie
72076 Tübingen / DE
02 / BUNK, Sebastian
72076 Tübingen / DE
03 / MAURER, Dominik
72076 Tübingen / DE
04 / WAGNER, Claudia
72076 Tübingen / DE
 [2022/30]
Representative(s)Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2022/30]
Application number, filing date21207265.607.12.2017
[2022/30]
Priority number, dateDE20161012384708.12.2016         Original published format: DE102016123847
US201662431588P08.12.2016         Original published format: US 201662431588 P
[2022/30]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP4032544
Date:27.07.2022
Language:EN
[2022/30]
Type: A3 Search report 
No.:EP4032544
Date:21.12.2022
Language:EN
[2022/51]
Search report(s)(Supplementary) European search report - dispatched on:EP18.11.2022
ClassificationIPC:A61K39/00, C07K14/725, C07K14/47
[2022/30]
CPC:
C07K14/4748 (EP,US); C07K14/7051 (EP,KR,US); A61K47/55 (US);
A61K35/17 (US); A61K38/1774 (US); A61K39/0011 (US);
A61K39/001186 (US); A61K39/4611 (EP,KR,US); A61K39/4632 (EP,US);
A61K39/464486 (EP,US); A61K39/464488 (EP,US); A61K47/64 (US);
A61P35/00 (EP,KR,US); C07K14/705 (EP,US); C07K16/30 (KR);
C12N15/85 (US); C12N5/00 (US); C12N5/0636 (EP,KR,US);
G01N33/57484 (KR); A61K2039/572 (EP,US); A61K38/00 (EP,US);
C07K14/70514 (EP,US); C07K14/70517 (EP,US); C07K2317/21 (US);
C07K2317/24 (US); C07K2317/565 (KR); C12N2510/00 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/29]
Former [2022/30]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA14.06.2023
ME14.06.2023
Validation statesMA14.06.2023
MD14.06.2023
TN14.06.2023
TitleGerman:NEUARTIGE T-ZELL-REZEPTOREN UND IMMUNTHERAPIE MIT VERWENDUNG DAVON[2022/30]
English:NOVEL T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME[2022/30]
French:NOUVEAUX RÉCEPTEURS DE LYMPHOCYTES T ET IMMUNOTHÉRAPIE LES UTILISANT[2022/30]
Examination procedure14.06.2023Amendment by applicant (claims and/or description)
14.06.2023Examination requested  [2023/29]
14.06.2023Date on which the examining division has become responsible
Parent application(s)   TooltipEP17829609.1  / EP3551221
Fees paidRenewal fee
28.12.2021Renewal fee patent year 03
28.12.2021Renewal fee patent year 04
28.12.2021Renewal fee patent year 05
15.12.2022Renewal fee patent year 06
11.12.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO2013039889  (US HEALTH [US], et al);
 [A]WO2014118236  (MAX DELBRÜCK CT FÜR MOLEDULARE MEDIZIN MDC BERLIN BUCH [DE]);
 [X]US2015337369  (DAVIS MARK M [US], et al);
 [AP]WO2017158103  (IMMATICS BIOTECHNOLOGIES GMBH [DE]);
 [T]WO2017216324  (MEDIGENE IMMUNOTHERAPIES GMBH [DE]);
 [T]WO2018170338  (HUTCHINSON FRED CANCER RES [US]);
 [T]WO2019067242  (US HEALTH [US]);
by applicantUS5545806
 US5569825
 US5714352
 US2002197266
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.